| Oct 30 |
Earnings Preview: Gilead Sciences (GILD) Q3 Earnings Expected to Decline
|
| Oct 29 |
Earnings Preview: IDEAYA Biosciences, Inc. (IDYA) Q3 Earnings Expected to Decline
|
| Oct 28 |
IDEAYA Biosciences Announces IND-Clearance for Werner Helicase Development Candidate IDE275 (GSK959) for a Phase 1 Study in MSI-High Solid Tumors
|
| Oct 25 |
IDEAYA reports Phase 1 expansion data for IDE397
|
| Oct 25 |
IDEAYA Announces Positive Interim Phase 1 Expansion Data of IDE397 in MTAP-Deletion Urothelial and Lung Cancer as Late-Breaker Oral Presentation at EORTC-NCI-AACR 2024
|
| Oct 24 |
UBS launches SMID cap biotechs with cancer, autoimmunity in focus
|
| Oct 4 |
IDEAYA Biosciences Announces Late-Breaker Oral Presentation of IDE397 Phase 1 Expansion Results in MTAP-Deletion Lung and Urothelial Cancer at the 36th Edition of the EORTC-NCI-AACR Symposium
|
| Sep 24 |
IDEAYA’s rare cancer drug shows promise as company lays out Phase III plans
|
| Sep 23 |
Ideaya Biosciences Stock Tumbles Despite Promising Data From Rare Eye Cancer Candidate
|
| Sep 23 |
IDEAYA Biosciences up on positive interim data for its uveal melanoma treatment
|
